Abstract
Modified hemoglobin preparations may potentially cause hypersensitivity and anaphylactic reactions, antibody-antigen reactions and other problems. Unfortunately response in animal safety studies may not reflect the same response in human. The next best test before clinical trial in human may the use of human plasma in-vitro. This paper present an in-vitro procedure based on complement activation (C3a) of human plasma. The procedure involves collecting heparinised blood and separating the plasma and freezing the heparinised plasma at -70 degrees C until use. Each 100 lambda of control or test samples is added to 400 lambda of this plasma. This is incubated at 37 degrees C, 60 rpm for 1 hour, then added to EDTA saline to stop the reaction and stored at -70 degrees C until analysed by standard radioimmunoassay for C3a. (C3 measurement is not sensitivity enough). Using the screening test procedure described above, C3a levels (ng/ml) in plasma were: control, 1,980 +/- 280; Zymosan, 20,000; Hemoglobin preparation A, 2,227 +/- 617; Hemoglobin preparation B, 4,967 +/- 153; A 75% + B 25%, 3,967 +/- 270; A 50% + B 50%, 4,553 +/- 517; A 25% + B 75%, 4,920 +/- 430. Hemoglobin preparation A did not cause significant increases in C3a complem...Continue Reading
References
Jan 1, 1990·Biomaterials, Artificial Cells, and Artificial Organs·L R ManningJ M Manning
Jan 1, 1990·Biomaterials, Artificial Cells, and Artificial Organs·J Ning, T M Chang
Jan 1, 1990·Biomaterials, Artificial Cells, and Artificial Organs·J Ning, T M Chang
Jan 1, 1988·Biomaterials, Artificial Cells, and Artificial Organs·M FeolaP C Canizaro
Jan 1, 1988·Biomaterials, Artificial Cells, and Artificial Organs·D E Hammerschmidt, G M Vercellotti
Jun 1, 1970·Revue française de transfusion·J MalgrasR Waitz
Citations
Jan 1, 1993·Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology·T M Chang, C W Lister
Jan 1, 1994·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·T M Chang, C W Lister
Jan 1, 1992·Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology·T M Chang
Jan 1, 1992·Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology·T M Chang, C Lister
Jan 1, 1992·Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology·T M Chang
Mar 9, 2010·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·Hongli ZhuThomas Ming Swi Chang
Dec 5, 2000·Baillière's Best Practice & Research. Clinical Haematology·T M Chang
Feb 1, 1992·Artificial Organs·T M Chang
Aug 17, 1995·Biochimica Et Biophysica Acta·W Kaca, R Roth